Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
[Update on Disclosed Matter] Notice Concerning Completion of Making Renalys Pharma, Inc. a Wholly-Owned Subsidiary and an Absorption-Type Merger
Corporate Governance Report
Eli Lilly’s Announcement Regarding Oral GLP-1 Orforglipron
Notice of Absorption-Type Merger of a Wholly-Owned Subsidiary, Renalys Pharma, Inc.
Notice Concerning Making Renalys Pharma, Inc. a Wholly-Owned Subsidiary
Supplementary Materials Consolidated Financial Statements for the nine months ended September 30, 2025 (IFRS)
CONSOLIDATED FINANCIAL STATEMENTS(IFRS)(Non-Audited)(for the nine months ended September 30, 2025)
CHUGAI PHARMA, Jan-Sep (Cumulative 3Q) Net Income Increases by 3%
F. Hoffmann-La Roche Announces Third Quarter Sales 2025
Chugai and Rani Therapeutics Enter into a License Agreement for the Development and Commercialization of an Oral Formulation
Eli Lilly's Announcement Regarding Oral GLP-1 Orforglipron
Eli Lilly's Announcement Regarding Oral GLP-1 Orforglipron
Chugai to Construct a New Laboratory Building "UKX" to Strengthen Manufacturing Process Development Capabilities and Advance Environmental Initiatives
Supplementary Materials Consolidated Financial Statements for the six months ended June 30, 2025 (IFRS)
CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the six months ended June 30, 2025)
CHUGAI PHARMA, Apr-Jun (2Q) Net Income Decreases by 13%
F. Hoffmann-La Roche Announces Half Year Results 2025
CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the three months ended March 31, 2025)
Supplementary Materials Consolidated Financial Statements for the three months ended March 31, 2025 (IFRS)
CHUGAI PHARMA, Jan-Mar (1Q) Net Income Increases by 31%